Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.

Zuercher AW, Horn MP, Que JU, Ruedeberg A, Schoeni MH, Schaad UB, Marcus P, Lang AB.

FEMS Immunol Med Microbiol. 2006 Jul;47(2):302-8.

2.

Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.

Lang AB, Rüdeberg A, Schöni MH, Que JU, Fürer E, Schaad UB.

Pediatr Infect Dis J. 2004 Jun;23(6):504-10.

PMID:
15194830
3.

Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.

Lehmann D, Kakazo M, Saleu G, Taime J, Javati A, Namuigi P, Alpers MP, Wegmüller B, Zellmeyer M, Fürer E, Que JU, Herzog C.

P N G Med J. 2001 Mar-Jun;44(1-2):6-16.

PMID:
12418673
4.

Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines.

Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R, Lell B, Que JU, Miller GB, Kremsner PG.

Clin Infect Dis. 2002 Nov 15;35(10):1147-54. Epub 2002 Oct 25.

PMID:
12410473
5.
6.

Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.

Panpitpat C, Thisyakorn U, Chotpitayasunondh T, Fürer E, Que JU, Hasler T, Cryz SJ Jr.

Bull World Health Organ. 2000;78(3):364-71.

7.

Immunotherapy of sepsis: flawed concept or faulty implementation?

Cross AS, Opal SM, Bhattacharjee AK, Donta ST, Peduzzi PN, Fürer E, Que JU, Cryz SJ.

Vaccine. 1999 Oct 1;17 Suppl 2:S13-21. Review.

PMID:
10506404
8.
9.

Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.

Richie E, Punjabi NH, Harjanto SJ, Wangsasaputral F, Sukandar M, Supriatman M, Simanjuntak CH, Que JU, Cryz SJ Jr.

Vaccine. 1999 Mar 17;17(11-12):1384-93.

PMID:
10195774
10.

Compatible concurrent administration of yellow fever 17D vaccine with oral, live, attenuated p6olera CVD103-HgR and typhoid ty21a vaccines.

Tsai TF, Kollaritsch H, Que JU, Cropp CB, Kunz C, Wiedermann G, Herzog C, Cryz SJ.

J Infect Dis. 1999 Feb;179(2):522-4. No abstract available.

PMID:
9878043
11.

Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients.

Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B, Glück R, Cryz SJ Jr.

Vaccine. 1997 Oct;15(15):1675-9.

PMID:
9364699
12.
13.

Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.

Chotpitayasunondh T, Panpitpat C, Thisyakorn U, Furer E, Que JU, Hasler T, Cryz SJ Jr.

Southeast Asian J Trop Med Public Health. 1997 Mar;28(1):91-8.

PMID:
9322290
14.

Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Cryz SJ Jr, Lang A, Rüdeberg A, Wedgwood J, Que JU, Fürer E, Schaad U.

Behring Inst Mitt. 1997 Feb;(98):345-9.

PMID:
9382759
15.
16.

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.

Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB, Strickland GT, Gordon DM, Ballou WR, Bales JD Jr, Wirtz RA, Wittes J, Gross M, Que JU, Cryz SJ, Oster CN, Roberts CR, Sadoff JC.

Vaccine. 1996 Jun;14(8):817-27.

PMID:
8817830
17.
18.
19.
20.

Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.

Rubinstein A, Goldstein H, Pettoello-Mantovani M, Mizrachi Y, Bloom BR, Furer E, Althaus B, Que JU, Hasler T, Cryz SJ.

AIDS. 1995 Mar;9(3):243-51.

PMID:
7755912
21.

Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine.

Cryz SJ Jr, Goldstein H, Pettoello-Mantovani M, Kim A, Fürer E, Que JU, Hasler T, Rubinstein A.

Vaccine. 1995 Jan;13(1):67-71.

PMID:
7762281
22.

Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.

Edelman R, Taylor DN, Wasserman SS, McClain JB, Cross AS, Sadoff JC, Que JU, Cryz SJ.

Vaccine. 1994 Nov;12(14):1288-94.

PMID:
7856293
23.

Immunogenicity of new virosome influenza vaccine in elderly people.

Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr.

Lancet. 1994 Jul 16;344(8916):160-3.

PMID:
7912766
24.

Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa.

Cryz SJ Jr, Wedgwood J, Lang AB, Ruedeberg A, Que JU, Fürer E, Schaad UB.

J Infect Dis. 1994 May;169(5):1159-62.

PMID:
8169414
25.

Prospects for prevention of vertical transmission of human immunodeficiency virus by immunization.

Cryz SJ Jr, Goldstein H, Fürer E, Que JU, Hasler T, Althaus B, Rubinstein A.

Ann N Y Acad Sci. 1993 Oct 29;693:194-201. Review. No abstract available.

PMID:
8267263
26.

Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.

Bruderer U, Cryz SJ Jr, Schaad UB, Deusinger M, Que JU, Lang AB.

J Infect Dis. 1992 Aug;166(2):344-9.

PMID:
1634805
27.

Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A.

Fries LF, Gordon DM, Schneider I, Beier JC, Long GW, Gross M, Que JU, Cryz SJ, Sadoff JC.

Infect Immun. 1992 May;60(5):1834-9.

28.

Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis.

Schaad UB, Lang AB, Wedgwood J, Ruedeberg A, Que JU, Fürer E, Cryz SJ Jr.

Lancet. 1991 Nov 16;338(8777):1236-7.

PMID:
1682645
29.

Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.

Cryz SJ Jr, Fürer E, Sadoff JC, Fredeking T, Que JU, Cross AS.

J Infect Dis. 1991 May;163(5):1055-61.

PMID:
1902245
30.

Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans.

Cryz SJ Jr, Cross AS, Sadoff JC, Wegmann A, Que JU, Fürer E.

J Infect Dis. 1991 May;163(5):1040-5.

PMID:
1708398
31.
32.

Clinical evaluation of an octavalent Pseudomonas aeruginosa conjugate vaccine in plasma donors and in bone marrow transplant and cystic fibrosis patients.

Cryz SJ Jr, Fürer E, Que JU, Sadoff JC, Brenner M, Schaad UB.

Antibiot Chemother (1971). 1991;44:157-62. No abstract available.

PMID:
1801634
33.

Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients.

Gottlieb DJ, Cryz SJ Jr, Furer E, Que JU, Prentice HG, Duncombe AS, Brenner MK.

Blood. 1990 Dec 15;76(12):2470-5.

34.

Immunological cross-reactivity between Enterobacter aerogenes and Klebsiella capsular polysaccharides.

Cryz SJ Jr, Pitt TL, Ayling-Smith B, Que JU.

Microb Pathog. 1990 Aug;9(2):127-30.

PMID:
2277587
35.

Effect of race and blood group on the immune response to bacterial polysaccharide and conjugate vaccines.

Cryz SJ Jr, Fürer E, Fredeking T, Cross AS, Sadoff JC, Que JU.

Lancet. 1989 Dec 23-30;2(8678-8679):1533-4. No abstract available.

PMID:
2574813
36.

Conjugate vaccines against Pseudomonas aeruginosa and malaria.

Cryz SJ Jr, Sadoff JC, Que JU.

Contrib Microbiol Immunol. 1989;10:166-89. Review. No abstract available.

PMID:
2510972
37.

Human IgG and IgA subclass response following immunization with a polyvalent Klebsiella capsular polysaccharide vaccine.

Cryz SJ Jr, Cross AS, Sadoff GC, Que JU.

Eur J Immunol. 1988 Dec;18(12):2073-5.

PMID:
3220104
38.

Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.

Que JU, Cryz SJ Jr, Ballou R, Fürer E, Gross M, Young J, Wasserman GF, Loomis LA, Sadoff JC.

Infect Immun. 1988 Oct;56(10):2645-9.

39.

Alteration of pulmonary structure by Pseudomonas aeruginosa exoenzyme S.

Woods DE, Hwang WS, Shahrabadi MS, Que JU.

J Med Microbiol. 1988 Jun;26(2):133-41.

PMID:
3133480
40.

Purification of Pseudomonas aeruginosa exoenzyme S.

Woods DE, Que JU.

Infect Immun. 1987 Mar;55(3):579-86.

41.

Alteration of lung structure and function by Pseudomonas aeruginosa.

Que JU, Woods DE.

Pathol Immunopathol Res. 1987;6(2):93-102. No abstract available.

PMID:
3122195
42.
43.

Supplemental Content

Support Center